 | |  | |  | |  | |  | |  | |  | |  |
| IJCEP Copyright © 2007-All rights reserved. |
| International Journal of Clinical and Experimental Pathology |
Int J Clin Exp Pathol 2(2),132-148;2009
Review Article
Mass Spectrometry-Based Proteomics and Peptidomics for Biomarker Discovery in
Neurodegenerative Diseases
Xin Wei and Lingjun Li
Department of Chemistry and School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, USA
Received 15 June 2008; Accepted and available online 20 June 2008
Abstract: There is an urgent need to search for biomarkers that are indicative of neurodegenerative diseases, as the clinical diagnosis of
which remains unsatisfactory. Mass spectrometry (MS) has been playing an important role in studying peptide and protein identities,
structures, modifications and interactions that collectively drive their biological functions. MS-based proteomics technology is thus well
suited for the biomarker discovery. This article reviews the overall strategies and workflows employed for biomarker discovery and recent
applications of MS-based proteomics in neurodegenerative diseases. Special emphasis is placed on the studies of protein
post-translational modification pattern changes and differential peptidomics under these pathological conditions.(IJCEP806008 ).
Key Words: Biomarker, neurodegenerative diseases, proteomics, peptidomics, post-translational modifications, mass spectrometry
Full text PDF
Address all correspondences to: Lingjun Li, PhD, School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, USA. Tel:
608-265-8491; Fax: 608-262-5345; Email: lli@pharmacy.wisc.edu
Review Article
Mass Spectrometry-Based Proteomics and Peptidomics for Biomarker Discovery in
Neurodegenerative Diseases
Xin Wei and Lingjun Li
Department of Chemistry and School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, USA
Received 15 June 2008; Accepted and available online 20 June 2008
Abstract: There is an urgent need to search for biomarkers that are indicative of neurodegenerative diseases, as the clinical diagnosis of
which remains unsatisfactory. Mass spectrometry (MS) has been playing an important role in studying peptide and protein identities,
structures, modifications and interactions that collectively drive their biological functions. MS-based proteomics technology is thus well
suited for the biomarker discovery. This article reviews the overall strategies and workflows employed for biomarker discovery and recent
applications of MS-based proteomics in neurodegenerative diseases. Special emphasis is placed on the studies of protein
post-translational modification pattern changes and differential peptidomics under these pathological conditions.(IJCEP806008 ).
Key Words: Biomarker, neurodegenerative diseases, proteomics, peptidomics, post-translational modifications, mass spectrometry
Full text PDF
Address all correspondences to: Lingjun Li, PhD, School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, USA. Tel:
608-265-8491; Fax: 608-262-5345; Email: lli@pharmacy.wisc.edu